<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867747</url>
  </required_header>
  <id_info>
    <org_study_id>ZKS-121-09</org_study_id>
    <nct_id>NCT03867747</nct_id>
  </id_info>
  <brief_title>Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias</brief_title>
  <acronym>RAVENTA</acronym>
  <official_title>Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias (RAVENTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with refractory ventricular extrasystoles or tachycardia not eligible for catheter&#xD;
      ablation will receive single fraction stereotactic body radiation therapy (cardiac&#xD;
      radiosurgery) with 25 Gy.&#xD;
&#xD;
      Investigators initiated this study to demonstrate that in at least 70% of the patients the&#xD;
      planned cardiac radiosurgery may be performed without any interruption or treatment related&#xD;
      interventional events within the first 30 days after treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint: 30-day post-intervention safety defined as presence of both, radiosurgery&#xD;
      delivery of the planned dose to the intended target area, and no possibly treatment related&#xD;
      serious adverse events in the first 30 days after treatment.&#xD;
&#xD;
      Secondary endpoints: evaluated at 1 year&#xD;
&#xD;
        -  Changes in ventricular tachycardia episodes and ICD shocks&#xD;
&#xD;
        -  Changes in antiarrhythmic medication due to treatment effects&#xD;
&#xD;
        -  Occurrence of possibly treatment related adverse events in the first year after&#xD;
           treatment (according to CTCAE v5.0)&#xD;
&#xD;
        -  Changes in patient-reported quality of life (recorded as EQ-5D-5L)&#xD;
&#xD;
        -  Overall survival&#xD;
&#xD;
        -  Safety profile&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity analysed by Adverse Event (AE)- and Serious Adverse Event (SAE)-reports</measure>
    <time_frame>30 days after radiosurgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late toxicity analysed by Adverse Event (AE)- and Serious Adverse Event (SAE)-reports</measure>
    <time_frame>12 months after radiosurgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular tachycardia burden reduction analysed by number of episodes and ICD shocks</measure>
    <time_frame>At the time of inclusion and 12 months after radiosurgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months after radiosurgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life questionnaire (EQ-5D-5L)</measure>
    <time_frame>At the time of inclusion and 12 months after radiosurgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Cardiac Radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 Gy in a single fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cardiac Radiosurgery</intervention_name>
    <description>Image-guided stereotactic body radiation therapy</description>
    <arm_group_label>Cardiac Radiosurgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with structural heart disease and implantable cardioverter defibrillator&#xD;
             (ICD)&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  either&#xD;
&#xD;
               1. Recurring symptomatic monomorphic ventricular tachycardia that requires ICD&#xD;
                  intervention (e.g. shock or anti-tachycardia stimulation). At least 3 episodes&#xD;
                  within the 3 months prior to inclusion or&#xD;
&#xD;
               2. induction of symptomatic monomorphic ventricular tachycardia that requires ICD&#xD;
                  intervention (e.g. shock or anti-tachycardia stimulation). Induction triggered by&#xD;
                  ICD or during electrophysiology studies (EPS) or both, a) and b)&#xD;
&#xD;
          -  Refractory to antiarrhythmic combination therapy&#xD;
&#xD;
          -  Beside the cardiac conditions: No competing illness that would additionally limit the&#xD;
             life expectancy to less than 6 months&#xD;
&#xD;
          -  No prior radiation therapy in the thorax area&#xD;
&#xD;
          -  No pregnancy and no active breastfeeding&#xD;
&#xD;
          -  Ability to consent and consent to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ICD electrode malfunction of ICD readings outside reference range&#xD;
&#xD;
          -  Lack of evidence of a myocardial scar (Computer tomography or magnetic resonance&#xD;
             tomography for MRI-capable ICD aggregates or electrophysiological measurement)&#xD;
&#xD;
          -  No possible induction of symptomatic monomorphic ventricular tachycardia&#xD;
             non-persistent or persistent with delivery of ICD therapies such as antitachycardic&#xD;
             pacing or shock&#xD;
&#xD;
          -  Contraindication to radiosurgery (e.g. precise target volume definition not possible&#xD;
             due to image artifacts created from a left ventricular assist device [LVAD])&#xD;
&#xD;
          -  Inability to consent or missing or withdrawn consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik Bonnemeier, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Schleswig-Holstein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juergen Dunst, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Schleswig-Holstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juergen Dunst, Prof.</last_name>
    <phone>+49431500</phone>
    <phone_ext>26501</phone_ext>
    <email>Juergen.Dunst@uksh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oliver Blanck, Dr.</last_name>
    <phone>+49431500</phone>
    <phone_ext>26501</phone_ext>
    <email>Oliver.Blanck@uksh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinic Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judit Boda-Heggemann, MD</last_name>
      <phone>+49621383</phone>
      <phone_ext>6020</phone_ext>
      <email>judit.boda-heggemann@umm.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Bürgy, MD</last_name>
      <phone>+49621383</phone>
      <phone_ext>6020</phone_ext>
      <email>daniel.buergy@medma.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Judit Boda-Heggemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Bürgy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Boris Rudic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Hohmann, MD</last_name>
      <phone>+49511532</phone>
      <phone_ext>3817</phone_ext>
      <email>Hohmann.Stephan@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Roland Merten, MD</last_name>
      <phone>+49511532</phone>
      <phone_ext>2574</phone_ext>
      <email>strahlentherapie@mh-hannover.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stephan Hohmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roland Merten, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Giordano, MD</last_name>
      <phone>+49228287</phone>
      <phone_ext>10354</phone_ext>
      <email>Frank.Giordano@ukbonn.de</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Beiert, MD</last_name>
      <phone>+49228287</phone>
      <phone_ext>15507</phone_ext>
      <email>Thomas.Beiert@ukbonn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Frank Giordano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Beiert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juergen Dunst, Prof.</last_name>
      <phone>+49431500</phone>
      <phone_ext>26501</phone_ext>
      <email>Juergen.Dunst@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Oliver Blanck, Dr.</last_name>
      <phone>+49431500</phone>
      <phone_ext>26501</phone_ext>
      <email>Oliver.Blanck@uksh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Juergen Dunst, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Krug, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Mehrhof, MD</last_name>
      <phone>+4930455</phone>
      <phone_ext>57088</phone_ext>
      <email>felix.mehrhof@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Leif-Hendrik Boldt, MD</last_name>
      <phone>+4930455</phone>
      <phone_ext>653722</phone_ext>
      <email>leif-hendrik.boldt@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Felix Mehrhof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leif-Hendrik Boldt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Blanck O, Buergy D, Vens M, Eidinger L, Zaman A, Krug D, Rudic B, Boda-Heggemann J, Giordano FA, Boldt LH, Mehrhof F, Budach V, Schweikard A, Olbrich D, König IR, Siebert FA, Vonthein R, Dunst J, Bonnemeier H. Radiosurgery for ventricular tachycardia: preclinical and clinical evidence and study design for a German multi-center multi-platform feasibility trial (RAVENTA). Clin Res Cardiol. 2020 Nov;109(11):1319-1332. doi: 10.1007/s00392-020-01650-9. Epub 2020 Apr 18.</citation>
    <PMID>32306083</PMID>
  </reference>
  <reference>
    <citation>Boda-Heggemann J, Blanck O, Mehrhof F, Ernst F, Buergy D, Fleckenstein J, Tülümen E, Krug D, Siebert FA, Zaman A, Kluge AK, Parwani AS, Andratschke N, Mayinger MC, Ehrbar S, Saguner AM, Celik E, Baus WW, Stauber A, Vogel L, Schweikard A, Budach V, Dunst J, Boldt LH, Bonnemeier H, Rudic B. Interdisciplinary Clinical Target Volume Generation for Cardiac Radioablation: Multicenter Benchmarking for the RAdiosurgery for VENtricular TAchycardia (RAVENTA) Trial. Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):745-756. doi: 10.1016/j.ijrobp.2021.01.028. Epub 2021 Jan 27.</citation>
    <PMID>33508373</PMID>
  </reference>
  <reference>
    <citation>Lydiard PGDip S, Blanck O, Hugo G, O'Brien R, Keall P. A Review of Cardiac Radioablation (CR) for Arrhythmias: Procedures, Technology, and Future Opportunities. Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):783-800. doi: 10.1016/j.ijrobp.2020.10.036. Epub 2020 Nov 5.</citation>
    <PMID>33160007</PMID>
  </reference>
  <reference>
    <citation>Krug D, Blanck O, Andratschke N, Guckenberger M, Jumeau R, Mehrhof F, Boda-Heggemann J, Seidensaal K, Dunst J, Pruvot E, Scholz E, Saguner AM, Rudic B, Boldt LH, Bonnemeier H. Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia. Heart Rhythm. 2021 Aug 8. pii: S1547-5271(21)02006-3. doi: 10.1016/j.hrthm.2021.08.004. [Epub ahead of print]</citation>
    <PMID>34380072</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Juergen Dunst, Prof.</investigator_full_name>
    <investigator_title>Prof. Dr. med. Juergen Dunst</investigator_title>
  </responsible_party>
  <keyword>Ventricular Tachycardia</keyword>
  <keyword>Stereotactic Body Radiation Therapy</keyword>
  <keyword>Radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Cardiac Complexes, Premature</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

